[Form 4] Edwards Lifesciences Corp Insider Trading Activity

Rhea-AI Filing Summary

Daveen Chopra, an officer (CVP, TMTT & Surgical) of Edwards Lifesciences Corporation (EW), received 3,205 restricted stock units (RSUs) on 09/11/2025 under the companys Long-Term Stock Incentive Compensation Program at an effective price of $0.0000. The RSUs are scheduled to vest in four equal annual installments beginning one year after the grant date. After this reported grant, the filing shows 34,201 shares beneficially owned by the reporting person. The Form 4 was signed by an attorney-in-fact and filed on 09/15/2025. The form notes it reflects changes in beneficial ownership only.

Insights

Corporate Governance Expert

TL;DR: Routine equity grant for retention; aligns executive incentives with shareholders without immediate dilution or cash expense.

The reported transaction is a standard long-term equity award: 3,205 RSUs granted under the issuers LTIP with vesting in four equal annual installments starting one year after grant. Such awards are typically used to retain senior personnel and align their interests with long-term shareholder value. The grant price is reported as $0.0000, consistent with restricted unit grants rather than an open-market purchase. This Form 4 discloses only the change in beneficial ownership and does not provide compensation valuation, expense recognition, or total outstanding dilution metrics.

Securities Analyst

TL;DR: Non-material insider grant disclosed; limited immediate market impact and no cash transaction recorded in the filing.

The filing documents an award of 3,205 RSUs to an officer, increasing reported beneficial ownership to 34,201 shares. Because RSUs vest over four years and no sale or purchase price is reported, the transaction does not represent an immediate cash flow or market sale. The Form 4 is informational for ownership tracking but lacks details on total outstanding share count or potential dilution, limiting assessment of material impact on EPS or ownership percentages.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chopra Daveen

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, TMTT & Surgical

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2025		A		3,205(1)	A	$0.0000	34,201	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These restricted stock units were granted on September 11, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for Edwards Lifesciences (EW)?

The Form 4 reports transactions by Daveen Chopra, an officer (CVP, TMTT & Surgical) of Edwards Lifesciences.

What securities were acquired in the Form 4 filed for EW?

The reporting person was granted 3,205 restricted stock units (RSUs) on 09/11/2025 under the companys Long-Term Stock Incentive Compensation Program.

When do the RSUs vest according to the filing?

The RSUs are scheduled to vest in four equal annual installments commencing one year after the grant date.

How many shares does the reporting person beneficially own after the grant?

Following the reported transaction the Form 4 shows 34,201 shares beneficially owned by the reporting person.

Was there any cash price paid for the RSUs in the filing?

The transaction is reported with a price of $0.0000, consistent with restricted unit grants rather than a cash purchase.